Want to see IKT full AI Analyst Report?
IKT Stock Chart & Stats
$2.49
$0.06(1.71%)
At close: 4:00 PM EST
$2.49
$0.06(1.71%)
Day’s Range― - ―
52-Week Range$1.33 - $2.61
Previous CloseN/A
Volume38.02K
Average Volume (3M)439.24K
Market Cap
$322.33M
Enterprise Value$195.36
Total Cash (Recent Filing)$159.02M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Nov 16, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding139,535,900
10 Day Avg. Volume346,592
30 Day Avg. Volume439,239
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.17
Price to Sales (P/S)0.00
P/FCF Ratio-7.25
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.40Price Target Upside157.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.44
Revenue Forecast (FY)$300.00K
Bulls Say, Bears Say
Bulls Say
Late-stage Phase 3 ProgressAdvancing a pivotal trial across a broad international site network moves IKT-001 closer to a regulatory decision and potential commercialization. The 505(b)(2) pathway may support a more efficient development route, while late-stage execution can improve the company’s strategic value if results are positive.
Orphan-drug Development AdvantagesOrphan designation strengthens the development framework for IKT-001 by providing regulatory and economic incentives in a high-unmet-need indication. If the therapy is approved, potential market exclusivity and trial-cost benefits could improve commercial durability and reduce development friction.
Low Financial LeverageA debt-free balance sheet reduces interest expense, refinancing exposure and fixed financial obligations while the company funds costly clinical development. This gives management greater flexibility to allocate capital toward IKT-001 and absorb trial volatility without the constraints associated with substantial leverage.
Bears Say
No Commercial Revenue And Widening LossesThe absence of sustained commercial revenue leaves the company dependent on financing and future clinical success rather than internally funded operations. Widening losses also reduce near-term earnings visibility and indicate that meaningful economic returns remain contingent on regulatory approval and commercialization.
Accelerating Cash BurnPersistent and increasing operating cash burn raises the amount of capital required to complete development and reach potential commercialization. Although free cash flow broadly tracks net loss, the absolute deficit still increases reliance on external funding and leaves less flexibility if clinical timelines or costs change.
Equity Dilution And Ownership ConcentrationFunding through large equity issuances expands the share base and can dilute existing holders, even as it supports the clinical program. The warrant exchange also preserves RA Capital’s economic exposure and may increase future ownership concentration, creating additional capital-structure and governance considerations.
Inhibikase Therapeutics News
IKT FAQ
What was Inhibikase Therapeutics’s price range in the past 12 months?
Inhibikase Therapeutics lowest stock price was $1.33 and its highest was $2.61 in the past 12 months.
What is Inhibikase Therapeutics’s market cap?
Inhibikase Therapeutics’s market cap is $322.33M.
When is Inhibikase Therapeutics’s upcoming earnings report date?
Inhibikase Therapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 60 days.
How were Inhibikase Therapeutics’s earnings last quarter?
Inhibikase Therapeutics released its earnings results on Aug 11, 2026. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.108 by -$0.002.
Is Inhibikase Therapeutics overvalued?
According to Wall Street analysts Inhibikase Therapeutics’s price is currently Undervalued.
Does Inhibikase Therapeutics pay dividends?
Inhibikase Therapeutics does not currently pay dividends.
What is Inhibikase Therapeutics’s EPS estimate?
Inhibikase Therapeutics’s EPS estimate is -0.11.
How many shares outstanding does Inhibikase Therapeutics have?
Inhibikase Therapeutics has 139,535,900 shares outstanding.
What happened to Inhibikase Therapeutics’s price movement after its last earnings report?
Inhibikase Therapeutics reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.108. Following the earnings report the stock price went down -2.041%.
Which hedge fund is a major shareholder of Inhibikase Therapeutics?
Currently, no hedge funds are holding shares in IKT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inhibikase Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.40 (157.03% Upside)
$6.40 (157.03% Upside)
Blogger Sentiment
Bullish
IKT Sentiment 100%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Decreased
By 2.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.07%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
84.11%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Inhibikase Therapeutics
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
IKT Stock 12 Month Forecast
Average Price Target
$6.40
▲(157.03% Upside)
Technical Analysis
Atossa Therapeutics
―
Anixa Biosciences
―
Spero Therapeutics
―
Surrozen
―
TScan Therapeutics
―
Ownership Overview
16.63% Insiders
5.14% Mutual Funds
65.06% Other Institutional Investors
5.35% Public Companies and
Individual Investors